» Articles » PMID: 10861320

Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease. National Acute Chest Syndrome Study Group

Overview
Journal N Engl J Med
Specialty General Medicine
Date 2000 Jun 22
PMID 10861320
Citations 324
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The acute chest syndrome is the leading cause of death among patients with sickle cell disease. Since its cause is largely unknown, therapy is supportive. Pilot studies with improved diagnostic techniques suggest that infection and fat embolism are underdiagnosed in patients with the syndrome.

Methods: In a 30-center study, we analyzed 671 episodes of the acute chest syndrome in 538 patients with sickle cell disease to determine the cause, outcome, and response to therapy. We evaluated a treatment protocol that included matched transfusions, bronchodilators, and bronchoscopy. Samples of blood and respiratory tract secretions were sent to central laboratories for antibody testing, culture, DNA testing, and histopathological analyses.

Results: Nearly half the patients were initially admitted for another reason, mainly pain. When the acute chest syndrome was diagnosed, patients had hypoxia, decreasing hemoglobin values, and progressive multilobar pneumonia. The mean length of hospitalization was 10.5 days. Thirteen percent of patients required mechanical ventilation, and 3 percent died. Patients who were 20 or more years of age had a more severe course than those who were younger. Neurologic events occurred in 11 percent of patients, among whom 46 percent had respiratory failure. Treatment with phenotypically matched transfusions improved oxygenation, with a 1 percent rate of alloimmunization. One fifth of the patients who were treated with bronchodilators had clinical improvement. Eighty-one percent of patients who required mechanical ventilation recovered. A specific cause of the acute chest syndrome was identified in 38 percent of all episodes and 70 percent of episodes with complete data. Among the specific causes were pulmonary fat embolism and 27 different infectious pathogens. Eighteen patients died, and the most common causes of death were pulmonary emboli and infectious bronchopneumonia. Infection was a contributing factor in 56 percent of the deaths.

Conclusions: Among patients with sickle cell disease, the acute chest syndrome is commonly precipitated by fat embolism and infection, especially community-acquired pneumonia. Among older patients and those with neurologic symptoms, the syndrome often progresses to respiratory failure. Treatment with transfusions and bronchodilators improves oxygenation, and with aggressive treatment, most patients who have respiratory failure recover.

Citing Articles

Combined use of respiratory multiplex PCR and procalcitonin to reduce antibiotic exposure in sickle-cell adult patients with acute chest syndrome (The ANTIBIO-STA study): a randomised, controlled, open-label trial.

Sabate-Elabbadi A, Mekontso-Dessap A, Lionnet F, Santin A, Verdet C, Woerther P Lancet Reg Health Eur. 2025; 51:101234.

PMID: 39995490 PMC: 11849121. DOI: 10.1016/j.lanepe.2025.101234.


Protocol for a multicentric, double-blind, randomised controlled trial of hyperbaric oxygen therapy (HBOT) versus sham for treating vaso-occlusive crisis (VOC) in sickle cell disease (SCD) in patients aged 8 years or older (HBOT-SCD study).

Stirnemann J, Serratrice J, Mann T, Louge P, Christophe C, Samii K BMJ Open. 2024; 14(11):e084825.

PMID: 39613437 PMC: 11605825. DOI: 10.1136/bmjopen-2024-084825.


Infections in sickle cell disease.

Scourfield L, Nardo-Marino A, Williams T, Rees D Haematologica. 2024; 110(3):546-561.

PMID: 39568431 PMC: 11873697. DOI: 10.3324/haematol.2024.285066.


Biomarkers to Differentiate Acute Chest Syndrome From Vaso-Occlusive Crisis in Children With Sickle Cell Disease.

Wang K, Olave N, Aggarwal S, Oh J, Patel R, Rahman A Eur J Haematol. 2024; 114(2):325-333.

PMID: 39498599 PMC: 11710972. DOI: 10.1111/ejh.14342.


Beyond Ischemia: The Rare Occurrence of Hemorrhagic Strokes in Pediatric Sickle Cell Anemia.

Mustafa M, Amawi M, Altoonisi M, Soliman W, Kamal M, Asaad Z Cureus. 2024; 16(10):e70871.

PMID: 39497863 PMC: 11532796. DOI: 10.7759/cureus.70871.